Obesity and insulin resistance in resistant hypertension: Implications for the kidney

Advances in Chronic Kidney Disease

Volumn 22, Issue 3, 2015, Pages 211-217

  Rao, Akhilesh ^a,b   Pandya, Vishwam ^a,b   Whaley Connell, Adam ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Endothelial dysfunction; Hypertension; Insulin resistance; Obesity; RAAS

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADIPONECTIN; ALDOSTERONE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CREATININE; DIACYLGLYCEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENZYME; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; LINOLEIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 2; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESISTIN; SODIUM PROTON EXCHANGE PROTEIN 3; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTERIAL STIFFNESS; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; HUMAN; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; MESANGIUM CELL; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SKELETAL MUSCLE; UREA NITROGEN BLOOD LEVEL; ADRENERGIC SYSTEM; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG RESISTANCE; HYPERTENSION; INFLAMMATION; KIDNEY; METABOLISM; VASCULAR ENDOTHELIUM; VASCULAR REMODELING;

DRUG RESISTANCE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; KIDNEY; OBESITY; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VASCULAR REMODELING;

EID: 84928011949     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.12.004     Document Type: Review

References (104)

1. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014, 311(8):806-814.
2. Yang Z., Zhang N. The burden of overweight and obesity on long-term care and Medicaid financing. Med Care 2014, 52(7):658-663.
3. Ferdinand K.C., Rodriguez F., Nasser S.A., et al. Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med 2014, 4(1):1-11.
4. Tanner R.M., Calhoun D.A., Bell E.K., et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013, 8(9):1583-1590.
5. Hall M.E., do Carmo J.M., da Silva A.A., et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014, 7:75-88.
6. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
7. Snyder J.J., Collins A.J. Association of preventive health care with atherosclerotic heart disease and mortality in CKD. J Am Soc Nephrol 2009, 20(7):1614-1622.
8. Whaley-Connell A., Sowers J.R., McCullough P.A., et al. Diabetes mellitus and CKD awareness: the kidney early evaluation program (KEEP) and national health and nutrition examination survey (NHANES). Am J Kidney Dis 2009, 53(4 suppl 4):S11-S21.
9. Saab G., Whaley-Connell A., Bombeck A., et al. The association between parathyroid hormone levels and the cardiorenal metabolic syndrome in non-diabetic chronic kidney disease. Cardiorenal Med 2011, 1(2):123-130.
10. Chen J., Muntner P., Hamm L.L., et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003, 14(2):469-477.
11. Park J., Ahmadi S.F., Streja E., et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014, 56(4):415-425.
12. Hanks L.J., Tanner R.M., Muntner P., et al. Metabolic subtypes and risk of mortality in normal weight, overweight, and obese individuals with CKD. Clin J Am Soc Nephrol 2013, 8(12):2064-2071.
13. Banerjee D., Recio-Mayoral A., Chitalia N., Kaski J.C. Insulin resistance, inflammation, and vascular disease in nondiabetic predialysis chronic kidney disease patients. Clin Cardiol 2011, 34(6):360-365.
14. Aroor A.R., McKarns S., DeMarco V.G., Jia G., Sowers J.R. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013, 62(11):1543-1552.
15. Duplain H., Burcelin R., Sartori C., et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001, 104(3):342-345.
16. Hale L.J., Coward R.J. The insulin receptor and the kidney. Curr Opin Nephrol Hypertens 2013, 22(1):100-106.
17. Campbell K.L., Kushner H., Falkner B. Obesity and high blood pressure: a clinical phenotype for the insulin resistance syndrome in African Americans. J Clin Hypertens (Greenwich) 2004, 6(7):364-370.
18. Brown N.K., Zhou Z., Zhang J., et al. Perivascular adipose tissue in vascular function and disease: a review of current Research and Animal models. Arterioscler Thromb Vasc Biol 2014, 34(8):1621-1630.
19. de Voorde J.V., Boydens C., Pauwels B., Decaluwe K. Perivascular adipose tissue, inflammation and vascular dysfunction in obesity. Curr Vasc Pharmacol 2014, 12(3):403-411.
20. Briones A.M., Aras-Lopez R., Alonso M.J., Salaices M. Small artery remodeling in obesity and insulin resistance. Curr Vasc Pharmacol 2014, 12(3):427-437.
21. Fujikawa R., Okubo M., Egusa G., Kohno N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study. Diabetes Res Clin Pract 2001, 53(2):99-106.
22. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998, 47(5):793-800.
23. DeMarco V.G., Aroor A.R., Sowers J.R. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol 2014, 10(6):364-376.
24. Sowers J.R., Whaley-Connell A., Hayden M.R. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med 2011, 1(1):5-12.
25. Falkner B., Cossrow N.D. Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States. Curr Hypertens Rep 2014, 16(7):449.
26. Guiducci L., Iervasi G., Quinones-Galvan A. On the paradox insulin resistance/insulin hypersensitivity and obesity: two tales of the same history. Expert Rev Cardiovasc Ther 2014, 12(6):637-642.
27. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148(5):852-871.
28. Zhang C., Wendel A.A., Keogh M.R., et al. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling. Proc Natl Acad Sci U S A 2012, 109(5):1667-1672.
29. Samuel V.T., Petersen K.F., Shulman G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010, 375(9733):2267-2277.
30. Szendroedi J., Yoshimura T., Phielix E., et al. Role of diacylglycerol activation of PKCtheta in lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci U S A 2014, 111(26):9597-9602.
31. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol 2014, 220(2):T1-T23.
32. Horita S., Seki G., Yamada H., et al. Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens 2011, 2011:391762.
33. Scherrer U., Randin D., Vollenweider P., Vollenweider L., Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994, 94(6):2511-2515.
34. Steinberg H.O., Chaker H., Leaming R., et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97(11):2601-2610.
35. Munzel T., Daiber A., Ullrich V., Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 2005, 25(8):1551-1557.
36. Raij L. Nitric oxide and cardiovascular and renal effects. Osteoarthritis Cartilage 2008, 16(suppl 2):S21-S26.
37. Hall J.E., Brands M.W., Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999, 892:91-107.
38. Zhang S.L., Chen X., Wei C.C., et al. Insulin inhibits dexamethasone effect on angiotensinogen gene expression and induction of hypertrophy in rat kidney proximal tubular cells in high glucose. Endocrinology 2002, 143(12):4627-4635.
39. Irving R.J., Noon J.P., Watt G.C., Webb D.J., Walker B.R. Activation of the endothelin system in insulin resistance. QJM 2001, 94(6):321-326.
40. Whaley-Connell A., DeMarco V.G., Lastra G., et al. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol 2008, 28(1):67-75.
41. Whaley-Connell A., Sowers J.R. Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep 2012, 14(4):360-365.
42. Wang C.J., Bao X.R., Du G.W., et al. Effects of insulin resistance on left ventricular hypertrophy in patients with CKD stage 1-3. Int Urol Nephrol 2014, 46(8):1609-1617.
43. Hale L.J., Hurcombe J., Lay A., et al. Insulin directly stimulates VEGF-A production in the glomerular podocyte. Am J Physiol Renal Physiol 2013, 305(2):F182-F188.
44. Pavlov T.S., Ilatovskaya D.V., Levchenko V., Li L., Ecelbarger C.M., Staruschenko A. Regulation of ENaC in mice lacking renal insulin receptors in the collecting duct. FASEB J 2013, 27(7):2723-2732.
45. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55(6):1537-1545.
46. Seven E., Husemoen L.L., Wachtell K., Ibsen H., Linneberg A., Jeppesen J.L. Overweight, adipocytokines and hypertension: a prospective population-based study. J Hypertens 2014, 32(7):1488-1494.
47. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86(5):1930-1935.
48. Cui J., Panse S., Falkner B. The role of adiponectin in metabolic and vascular disease: a review. Clin Nephrol 2011, 75(1):26-33.
49. Yadav A., Kataria M.A., Saini V., Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013, 417:80-84.
50. de Faria A.P., Modolo R., Fontana V., Moreno H. Adipokines: novel players in resistant hypertension. J Clin Hypertens (Greenwich ) 2014, 16(10):754-759.
51. Adamczak M., Wiecek A., Funahashi T., et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003, 16(1):72-75.
52. Rojas E., Rodriguez-Molina D., Bolli P., et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 2014, 16(8):463.
53. Baden M.Y., Yamada Y., Takahi Y., et al. Association of adiponectin with blood pressure in healthy people. Clin Endocrinol (Oxf) 2013, 78(2):226-231.
54. Wang Z.V., Scherer P.E. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008, 51(1):8-14.
55. Sharma K., Ramachandrarao S., Qiu G., et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008, 118(5):1645-1656.
56. Rossi G.P., Cesari M., Cuspidi C., et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013, 62(1):62-69.
57. Calhoun D.A. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006, 48(6):387-396.
58. Rocchini A.P., Katch V.L., Grekin R., Moorehead C., Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986, 57(8):613-618.
59. Briones A.M., Nguyen Dinh C.A., Callera G.E., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012, 59(5):1069-1078.
60. Jeon J.H., Kim K.Y., Kim J.H., et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008, 22(5):1502-1511.
61. Schinner S., Willenberg H.S., Krause D., et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond) 2007, 31(5):864-870.
62. Goodfriend T.L., Ball D.L., Egan B.M., Campbell W.B., Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004, 43(2):358-363.
63. Yao L., Herlea-Pana O., Heuser-Baker J., Chen Y., Barlic-Dicen J. Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease. J Immunol Res 2014, 2014:181450.
64. Oh D.Y., Morinaga H., Talukdar S., Bae E.J., Olefsky J.M. Increased macrophage migration into adipose tissue in obese mice. Diabetes 2012, 61(2):346-354.
65. Kumar H., Kawai T., Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009, 388(4):621-625.
66. Lumeng C.N. Innate immune activation in obesity. Mol Aspects Med 2013, 34(1):12-29.
67. Ilan Y., Maron R., Tukpah A.M., et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A 2010, 107(21):9765-9770.
68. Kamei N., Tobe K., Suzuki R., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006, 281(36):26602-26614.
69. Ji Y., Liu J., Wang Z., Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009, 23(4-6):265-276.
70. De Batista P.R., Palacios R., Martin A., et al. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS One 2014, 9(8):e104020.
71. Bondeva T., Roger T., Wolf G. Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites. Am J Nephrol 2007, 27(3):308-314.
72. Ruster C., Bondeva T., Franke S., et al. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol 2009, 29(6):538-550.
73. Wolf G., Bohlender J., Bondeva T., et al. Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol 2006, 17(6):1585-1593.
74. Wang M.C., Tsai W.C., Chen J.Y., Huang J.J. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005, 45(3):494-501.
75. Collier S.R., Sandberg K., Moody A.M., et al. Reduction of plasma aldosterone and arterial stiffness in obese pre- and stage1 hypertensive subjects after aerobic exercise. J Hum Hypertens 2005, 29(1):53-57.
76. Underwood P.C., Adler G.K. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 2013, 15(1):59-70.
77. Hayden M.R., Sowers K.M., Pulakat L., et al. Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus. Cardiorenal Med 2011, 1(3):193-210.
78. Kang Y.S. Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press 2013, 11(2):46-52.
79. Igarashi M., Hirata A., Nozaki H., Kadomoto-Antsuki Y., Tominaga M. Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Diabetes Res Clin Pract 2007, 75(3):267-277.
80. Brillante D.G., O'Sullivan A.J., Howes L.G. Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. Vasc Health Risk Manag 2009, 5(1):73-78.
81. Brillante D.G., O'Sullivan A.J., Johnstone M.T., Howes L.G. Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diabetes Obes Metab 2008, 10(2):143-150.
82. Jia G., Aroor A.R., Sowers J.R. Arterial stiffness: A nexus between cardiac and renal disease. Cardiorenal Med 2014, 4(1):60-71.
83. Pulakat L., DeMarco V.G., Whaley-Connell A., Sowers J.R. The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med 2011, 1(2):102-112.
84. Aroor A.R., DeMarco V.G., Jia G., et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) 2013, 4:161.
85. van Bussel B.C., Schouten F., Henry R.M., et al. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension 2011, 58(4):588-595.
86. Mollnau H., Wendt M., Szocs K., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002, 90(4):E58-E65.
87. Lambeth J.D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004, 4(3):181-189.
88. Kim J.A., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113(15):1888-1904.
89. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150(11):776-783.
90. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr Res 1998, 24(3-4):789-796.
91. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
92. Nelson R.G., Tuttle K.R. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif 2007, 25(1):112-114.
93. Vejakama P., Thakkinstian A., Lertrattananon D., et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012, 55(3):566-578.
94. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342(13):905-912.
95. Weir M.R., Reisin E., Falkner B., et al. Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. Am J Hypertens 1998, 11(8 Pt 1):914-920.
96. Sharma A.M., Pischon T., Engeli S., Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?. J Hypertens 2001, 19(4):667-674.
97. Scholze J., Grimm E., Herrmann D., Unger T., Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115(15):1991-1998.
98. Weinberger M.H., Izzo J.L., Purkayastha D., Weitzman R., Black H.R. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens 2011, 5(6):489-497.
99. Roth E.M., Oparil S., Melino M., et al. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich ) 2013, 15(8):584-592.
100. Calhoun D.A. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013, 64:233-247.
101. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49(4):839-845.
102. Kumar N., Calhoun D.A., Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control 2013, 6:139-151.
103. Wang B., Zhong J., Lin H., et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013, 15(8):737-749.
104. Gilbert K., Nian H., Yu C., Luther J.M., Brown N.J. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens 2013, 31(4):820-829.